Cancer

Health Canada Grants Device License for iCAD’s ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment

NASHUA, N.H., Aug. 16, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer…

11 months ago

Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development

Dr. Davarpanah will lead Cidara’s oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational…

11 months ago

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with…

11 months ago

Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers

Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 Study Designed to Support Planned…

11 months ago

Promore Pharma Engages Erik Penser Bank as Liquidity Provider

STOCKHOLM, SWEDEN / ACCESSWIRE / August 16, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) Promore Pharma AB (publ) today announced that the…

11 months ago

AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

Pivotal Milestone Accelerates Pathway to Specific IndicationLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused…

11 months ago

Elevar Therapeutics Names Dr. Chris Galloway Vice President of Clinical Development

FORT LEE, N.J., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and…

11 months ago

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5…

11 months ago